Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of the project is to improve the overall treatment and outcome of renal, pancreas or liver transplanted patients who have encountered a malignancy by a structured treatment program for diagnosis and treatment of the malignancy, optimization of the immunosuppressive treatment, follow-up and evaluation of the program.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Malignancy post transplantation |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Referral to a multidisciplinary expert panel at the Uppsala University Hospital after tumor detection | Other |
| ||
| Measure | Description | Time Frame |
|---|---|---|
| Patient survival | After inclusion | 12 months, 2 years, 3 years |
| Measure | Description | Time Frame |
|---|---|---|
| Graft survival | After inclusion | 12 months, 2 years, 3 years |
| ImmuKnow Assay value | 12 months | |
| Tumour progression/regression/reoccurrence |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Kidney, pancreas or liver transplanted patients in the Uppsala/Örebro region with a diagnosed malignancy pre or post transplantation
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Surgery, Section of Transplantation Surgery, Uppsala University Hospital | Uppsala | SE-75185 | Sweden |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 27163539 | Background | Hellstrom V, Lorant T, Dohler B, Tufveson G, Enblad G. High Posttransplant Cancer Incidence in Renal Transplanted Patients With Pretransplant Cancer. Transplantation. 2017 Jun;101(6):1295-1302. doi: 10.1097/TP.0000000000001225. | |
| 26824275 | Derived | Hellstrom VC, Enstrom Y, von Zur-Muhlen B, Hagberg H, Laurell A, Nyberg F, Backman L, Opelz G, Dohler B, Holmberg L, Tufveson G, Enblad G, Lorant T. Malignancies in transplanted patients: Multidisciplinary evaluation and switch to mTOR inhibitors after kidney transplantation - experiences from a prospective, clinical, observational study. Acta Oncol. 2016 Jun;55(6):774-81. doi: 10.3109/0284186X.2015.1130855. Epub 2016 Jan 29. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Switch from calcineurin inhibitor to an mTOR inhibitor |
| Drug |
|
| 12 months, 2 years, 3 years |
| Maintained switch of immunosuppression from calcineurin inhibitor to mTOR inhibitor | 3 years |
| Kidney function | Creatinine measure | 12 months, 2 years, 3 years |